slamming on the rnai brakes, page-9

Enumerate,
Enjoyed your series of posts. Interesting article in Forbes titled Big Pharma's Turn On RNAi Shows That New Technologies Don't Guarantee R&D Success, 15 April 2014;

"However, the biggest hurdle for RNAi is delivery of such a therapy to the target organ as these large molecules are easily broken down in the body."

Phylogica have identified siRNA as one of the therapies which its CPPs are able to deliver to the tissue type of interest. The targeted intracellular delivery of siRNA may breathe new life into the process of RNA interference which had been heralded as a major scientific once-in-a-decade breakthrough.